Login to Continue Learning
For instance, Wedbush analyst Dan Ives anticipates a significant demand for the new iPhone 17 series:
> “We estimate roughly 315 million out of 1.5 billion global iPhone users haven’t upgraded in over four years, indicating an upgrade opportunity on the horizon.”
Ives expects this to lead to a supercycle for Apple within the next 12 to 18 months, which he believes will be bolstered by an expected revamp of Apple’s intelligence capabilities in spring 2026.
Meanwhile, Evercore ISI analyst Amit Daryanani suggests that the new Apple Watch Ultra 3 might qualify for HSA approval due to its blood pressure monitoring features:
> “The blood pressure monitoring on the new Apple Watch is noteworthy and could enable it to be considered an HSA-approved device, unlocking additional purchases.”
For context, an HSA-approved device allows pre-tax funds from a Health Savings Account to be used for purchase.
It’s important to note that while the Apple Watch Ultra 3 can detect blood pressure patterns over time, its accuracy may not match medical-grade devices.
Finally, UBS analyst David Vogt has conducted a back-of-the-envelope calculation and concluded that Apple’s average selling price (ASP) is likely to increase by about 3.5 percent. This rise in ASP will be partly offset by the increased Bill of Materials (BoM), resulting from the removal of the 128GB storage configuration in the base, Air, and Pro variants of the iPhone 17:
> “Assuming a similar production and sell-through mix as last year, with the Base and Pro Max accounting for roughly two-thirds of iPhone sales, pricing could be up about 3.5 percent YoY. The removal of the 128GB storage configuration in three models (Base, Air, and Pro) could increase the blended iPhone BOM by around 1.5 to 2.0 percent, slightly offsetting the price uplift.”
